In vitro activity of eugenol against Candida albicans biofilms

Mycopathologia

Volumn 163, Issue 3, 2007, Pages 137-143

  He, Miao ^a   Du, Minquan ^a   Fan, Mingwen ^a   Bian, Zhuan ^a  

^a WUHAN UNIVERSITY   (China)

Author keywords

Biofilm; Candida albicans; Clove essential oil; Eugenol

Indexed keywords

ANTIFUNGAL AGENT; EUGENOL;

ARTICLE; BIOFILM; CANDIDA ALBICANS; CYTOLOGY; DRUG EFFECT; ERYTHROCYTE; HEMOLYSIS; HUMAN; IC 50; PHYSIOLOGY;

ANTIFUNGAL AGENTS; BIOFILMS; CANDIDA ALBICANS; ERYTHROCYTES; EUGENOL; HEMOLYSIS; HUMANS; INHIBITORY CONCENTRATION 50;

CANDIDA ALBICANS; SYZYGIUM AROMATICUM;

EID: 33947499532     PISSN: 0301486X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11046-007-0097-2     Document Type: Article

References (27)

1. Jarvis WR. Epidemiology of nosocomial fungal infections, with emphasis on Candida species. Clin Infect Dis 1995; 20: 1526-1530.
2. Ramage G, Vandewalle K, Wickes BL, Lopez-Ribot JL. Characteristics of biofilm formation by Candida albicans. Rev Iberoam Micol 2001; 18: 163-170.
3. Sandven P. Epidemiology of candidemia. Rev Iberoam Micol 2000; 17: 73-81.
4. Bachmann SP, VandeWalle K, Ramage G, Patterson TF, Wickes BL, Graybill JR, Lopez-Ribot JL. In vitro activity of caspofungin against Candida albicans biofilms. Antimicrob Agents Chemother 2002; 46: 3591-3596.
5. Alexander BD, Perfect JR. Antifungal resistance trends towards the year 2000. Implications for therapy and new approaches. Drugs 1997; 54: 657-678.
6. Donlan RM. Biofilm formation: a clinically relevant microbiological process. Clin Infect Dis 2001; 33: 1387-1392.
7. Douglas LJ. Candida biofilms and their role in infection. Trends Microbiol 2003; 11: 30-36.
8. Kojic EM, Darouiche RO. Candida infections of medical devices. Clin Microbiol Rev 2004; 17: 255-267.
9. Ramage G, Saville SP, Thomas DP, Lopez-Ribot JL. Candida biofilms: an update. Eukaryot Cell 2005; 4: 633-638.
10. Chami N, Bennis S, Chami F, Aboussekhra A, Remmal A. Study of anticandidal activity of carvacrol and eugenol in vitro and in vivo. Oral Microbiol Immunol 2005; 20: 106-111.
11. Situ H, Bobek LA. In vitro assessment of antifungal therapeutic potential of salivary histatin-5, two variants of histatin-5, and salivary mucin (MUC7) domain 1. Antimicrob Agents Chemother 2000; 44: 1485-1493.
12. Deans SG, Subota KP, Kennedy AI. Biological activity of plant volatile oils and their constituents. Planta Med 1989; 55: 588.
13. Janssen AM, Scheffer JJ, Baerheim Svendsen A. Antimicrobial activity of essential oils: a 1976-1986 literature review. Aspects of the test methods. Planta Med 1987; 53: 395-398.
14. Tampieri MP, Galuppi R, Macchioni F, Carelle MS, Falcioni L, Cioni PL, Morelli I. The inhibition of Candida albicans by selected essential oils and their major components. Mycopathologia 2005; 159: 339-345.
15. Ou HC, Chou FP, Lin TM, Yang CH, Sheu WH. Protective effects of eugenol against oxidized LDL-induced cytotoxicity and adhesion molecule expression in endothelial cells. Food Chem Toxicol 2006; 44: 1485-1495.
16. Nangle MR, Gibson TM, Cotter MA, Cameron NE. Effects of eugenol on nerve and vascular dysfunction in streptozotocin-diabetic rats. Planta Med 2006; 72: 494-500.
17. Guenette SA, Beaudry F, Marier JF, Vachon P. Pharmacokinetics and anesthetic activity of eugenol in male Sprague-Dawley rats. J Vet Pharmacol Ther 2006; 29: 265-270.
18. Cassanho AC, Fernandes AM, Oliveira LD, Carvalho CA, Jorge AO, Koga-Ito CY. In vitro activity of zinc oxide-eugenol and glass ionomer cements on Candida albicans. Pesqui Odontol Bras 2005; 19: 134-138.
19. Miyakawa Y, Mabuchi T, Fukazawa Y. New method for detection of Candida albicans in human blood by polymerase chain reaction. J Clin Microbiol 1993; 31: 3344-3347.
20. Zipkes MR, Gilchrist JE, Peeler JT. Comparison of yeast and mold counts by spiral, pour, and streak plate methods. J Assoc Off Anal Chem 1981; 64: 1465-1469.
21. Tortorano AM, Prigitano A, Biraghi E, Viviani MA, FIMUA-ECMM Candidaemia Study Group. The European Confederation of Medical Mycology (ECMM) survey of candidaemia in Italy: in vitro susceptibility of 375 Candida albicans isolates and biofilm production. J Antimicrob Chemother 2005; 56: 777-779.
22. Wei GX, Bobek LA. In vitro synergic antifungal effect of MUC7 12-mer with histatin-5 12-mer or miconazole. J Antimicrob Chemother 2004; 53: 750-758.
23. Ramage G, Van de Walle K, Wickes BL, Lopez-Ribot JL. Standardized method for in vitro antifungal susceptibility testing of Candida albicans biofilms. Antimicrob Agents Chemother 2001; 45: 2475-2479.
24. White TC, Marr KA, Bowden RA. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev 1998; 11: 382-402.
25. Kauffman CA, Carver PL. Antifungal agents in the 1990s. Current status and future developments. Drugs 1997; 53: 539-549.
26. Alem MA, Douglas LJ. Effects of aspirin and other nonsteroidal anti- inflammatory drugs on biofilms and planktonic cells of Candida albicans. Antimicrob Agents Chemother 2004; 48: 41-47.
27. Lopez-Ribot JL. Candida albicans biofilms: more than filamentation. Curr Biol 2005; 15: R453-R455.